Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Research reports from C.S.M. Diefenbach and co-authors provide new insights into immunization
June 25th, 2008
"The cancer-testis antigen NY-ESO-1 is expressed by > 40% of advanced epithelial ovarian cancers and is a promising immunotherapeutic target. In this study, we describe the effects of vaccination with the HLA-A*0201 -restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission," scientists in the United States report. "After primary surgery and chemotherapy, high-risk epithelial ovarian cancer patients in first clinical remission received NY-ESO-1b peptide and Montanide every 3 weeks for five vaccinations. Tumor expression was evaluated by immunohistochemistry. Toxicity was monitored using National Cancer Institute Common...
Source: Vaccine Weekly (2008-06-25)
|
